Pfizer asks U.S. to allow COVID-19 shots for kids ages 5 to 11
CBC
Pfizer asked the U.S. government Thursday to allow the use of its COVID-19 vaccine in children ages five to 11 — and if regulators agree, shots could begin within a matter of weeks.
Many parents and pediatricians are clamouring for protection for children younger than 12, today's age cut-off for the vaccine made by Pfizer and its German partner BioNTech. Not only can youngsters sometimes get seriously ill, but keeping them in school can be a challenge with the coronavirus still raging in poorly vaccinated communities.
Pfizer announced in a tweet that it had formally filed its application with the Food and Drug Administration.
Now the FDA will have to decide if there's enough evidence that the shots are safe and will work for younger children like they do for teens and adults. An independent expert panel will publicly debate the evidence on Oct. 26.
One big change: Pfizer says its research shows the younger kids should get a third of the dose now given to everyone else. After their second dose, the five- to 11-year-olds developed virus-fighting antibody levels just as strong as teens and young adults get from regular-strength shots.
While kids are at lower risk of severe illness or death than older people, COVID-19 does sometimes kill children and cases in youngsters have skyrocketed as the extra-contagious delta variant has swept through the country
"It makes me very happy that I am helping other kids get the vaccine," said Sebastian Prybol, 8, of Raleigh, N.C. He is enrolled in Pfizer's study at Duke University and doesn't yet know if he received the vaccine or dummy shots.